Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant (Cervarix)

Elliott, William T.; Chan, James
December 2009
Internal Medicine Alert;12/29/2009, Vol. 31 Issue 24, p190
Product Review
The article evaluates Cervarix, a human papillomavirus (HPV) bivalent and recombinant vaccine for Types 16 and 18 from GlaxoSmithKline.


Related Articles

  • A semi-qualitative study of attitudes to vaccinating adolescents against human papillomavirus without parental consent. Brabin, Loretta; Roberts, Stephen A.; Kitchener, Henry C. // BMC Public Health;2007, Vol. 7 Issue 1, p20 

    Background: The first vaccine to prevent human papillomavirus (HPV) and cervical cancer has been licensed, and in future, vaccination may be routinely offered to 10-14 year old girls. HPV is a sexually transmitted virus and some parents may refuse consent for vaccination. Under-16s in the UK...

  • Appendix 2: Model NRA Lot Release Certificate for recombinant human papillomavirus virus-like particle vaccines.  // WHO Technical Report Series;2016, Issue 999, p232 

    An appendix is presented of model NRA Lot Release Certificate for recombinant human papillomavirus virus-like particle vaccines from the World Health Organization Expert Committee on Biological Standardization.

  • Antibody Responses in Oral Fluid after Administration of Prophylactic Human Papillomavirus Vaccines. Rowhani-Rahbar, Ali; Carter, Joseph J.; Hawes, Stephen E.; Hughes, James P.; Weiss, Noel S.; Galloway, Denise A.; Koutsky, Laura A. // Journal of Infectious Diseases;11/1/2009, Vol. 200 Issue 9, p1452 

    We sought to determine whether oral fluid can be used to assess serum human papillomavirus (HPV) antibody status by enrolling women who had received a prophylactic HPV-16 vaccine in a new follow-up study. After the prophylactic HPV-6/11/16/18 vaccine was licensed in the United States, we...

  • Monitoring the coverage and impact of human papillomavirus vaccine -- report of WHO meeting, November 2009.  // Weekly Epidemiological Record;6/18/2010, Vol. 85 Issue 25, p237 

    The article reports on the coverage and impact monitoring of the human pappilomavirus vaccine (HPV). It states that monitoring vaccine coverage of HPV is valuable in the evaluation of vaccine programs and vaccine impact. It also cites several possible biological resultants for the monitoring...

  • US Panel Backs HPV Vaccine for Males.  // Clinical Infectious Diseases;11/1/2009, Vol. 49 Issue 9, pii 

    The article reports on a vaccine developed by Merk & Co. Inc. for the prevention of human papillomavirus (HPV) infection that causes cervical cancer and genital warts. According to the Food and Drug Administration advisory panel in the U.S., Gardasil vaccine is safe and effective to prevent...

  • Global Advisory Committee on Vaccine Safety, 5-6 June 2019.  // Weekly Epidemiological Record;7/12/2019, Vol. 94 Issue 28, p309 

    The article discusses the highlights of the 40th meeting of the Global Advisory Committee on Vaccine Safety in Geneva, Switzerland on June 5 and 6, 2019. Topics covered include the clinical development of Ebola virus vaccines, the use of a network of distributed data to monitor the safety of...

  • CERVARIX.  // Physician Assistants' Prescribing Reference;Spring2010, Vol. 17 Issue 1, pA9 

    The article evaluates the Cervarix pappillomavirus vaccine from GlaxoSmithKline.

  • COMPARING HPV VACCINES.  // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;10/22/2011, Vol. 343 Issue 7828, p809 

    No abstract available.

  • US committee recommends HPV vaccine for boys. Roehr, Bob // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;11/5/2011, Vol. 343 Issue 7830, p927 

    The article reports on a U.S. committee, which recommended mandatory quadrivalent vaccination to all boys in the U.S. against human papillomavirus (HPV) infection.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics